Items Tagged ‘metastatic’

December 5th, 2016

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

By

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of […]

View full entry

Tags: AXL, Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, MET, metastatic, mRCC, News, Renal Cancer, sunitinib, Sutent


September 20th, 2016

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

By

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination being considered as a new standard of care for patients with this disease. These results were recently published in the Lancet Oncology. Melanoma is a […]

View full entry

Tags: advanced, BRAF V600, cobimetinib, combination, Melanoma, metastatic, News, Stage III Melanoma, Stage IV Melanoma, vemurafenib


September 7th, 2016

Keytruda® Approved for Advanced Head and Neck Cancer

By

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck squamous cell cancer […]

View full entry

Tags: advanced, fda, General Head and Neck Cancer, Head and Neck Cancer, keytruda, metastatic, News, pembrolizumab


September 5th, 2016

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer

By

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence.” These updates were recently published in the Journal of Clinical […]

View full entry

Tags: Breast Cancer, Endocrine therapy, hormone-receptor (HR)-positive, hormones, metastatic, Metastatic Breast Cancer, News, recommendation


August 22nd, 2016

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment

By

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed […]

View full entry

Tags: advanced, asco, cytoreductive surgery, epithelial, metastatic, NACT, News, Ovarian Cancer, SGO, Stage II-IV Ovarian Cancer


June 8th, 2016

Long-Lasting Responses Achieved with Keytruda® in Advanced Head and Neck Cancer

By

Treatment with the immune-stimulating agent, Keytruda® (pembrolizumab), provides impressive long-term outcomes for some patients with metastatic or recurrent head and neck cancer. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Globally, head and neck cancer comprises the seventh most common type of cancer with an […]

View full entry

Tags: advanced, ASCO 2016, General Head and Neck Cancer, Head and Neck Cancer, HNSCC, KEYNOTE-012, keytruda, metastatic, News, perbrolizumab, squamous cell cancer


May 10th, 2016

Cabometyx® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy. Each year in the United States, more than 61,000 people are diagnosed […]

View full entry

Tags: Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, kinase inhibitor, metastatic, News, rcc, Renal Cancer, renal cell carcinoma


March 17th, 2016

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer

By

The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor receptor-2 (HER2)-negative, metastatic breast cancer that has progressed following prior endocrine (hormone) therapy. The majority of breast cancers are HR-positive. These cancers are stimulated to grow by the […]

View full entry

Tags: approval, Breast Cancer, Faslodex, fda, fulvestrant, HER2-negative, hormone-positive, Ibrance, metastatic, Metastatic Breast Cancer, News, palbociclib


January 3rd, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. and […]

View full entry

Tags: Breast Cancer, HER2-positive, metastatic, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, T-DMI, TH3RESA trial, trastuzumab emtansine


December 2nd, 2015

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

By

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The indication for this expanded approval specifies that Opdivo can be used for treatment […]

View full entry

Tags: advanced, CheckMate -066 trial, Melanoma, metastatic, News, opdivo, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


October 12th, 2015

Opdivo® Improves Survival in Kidney Cancer

By

The immunotherapy agent, Opdivo® (nivolumab), improves survival in kidney cancer compared to the standard treatment, Afinitor® (everolimus). These results were recently published in the New England Journal of Medicine. About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are diagnosed with kidney cancer. The most common type of kidney cancer […]

View full entry

Tags: afinitor, kidney cancer, metastatic, News, opdivo, rcc, Renal Cancer, renal cell carcinoma


October 9th, 2015

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended […]

View full entry

Tags: abemaciclib, Breast Cancer, CDK, hormone-receptor positive, HR+, metastatic, Metastatic Breast Cancer, MONARCH 3, News, Recurrent Breast Cancer


September 29th, 2015

No Benefit with Addition of Onartuzumab to Taxol® with or without Avastin® in Triple-Negative Breast Cancer

By

The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are […]

View full entry

Tags: avastin, Breast Cancer, metastatic, Metastatic Breast Cancer, Onatuzumab, Taxol, triple negative


September 9th, 2015

Lynparza Improves Overall Survival in High-Risk Gastric Cancer

By

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 Americans will be diagnosed with gastric […]

View full entry

Tags: ATM, Gastric Cancer, lynparza, metastatic, News, olaparib, paclitaxel, PARP inhibitor, Stages III-IV Gastric Cancer


June 23rd, 2015

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

By

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal […]

View full entry

Tags: Colon Cancer, colorectal cancer, irinotecan, metastatic, News, oxaliplatin, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer